Michael Klichinsky sold $124k of CARM
Chief Scientific Officer at Carisma Therapeutics Inc.. 484,347 shares at an average of $0.26, traded Oct 1, 2025, filed Oct 3, 2025.
Score components
- +15RoleOfficer
- +10Trade size$124k at market
- +20Share of holdings soldSold 100% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -78.4%, 3m -83.1%, 6m -87.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-25-096740, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 1, 2025 | SOpen-market sale Common Stock | -165,000 | $0.26 | $42k | 319,347 | Oct 3, 2025 |
| Oct 2, 2025 | SOpen-market sale Common Stock | -200,000 | $0.25 | $51k | 119,347 | Oct 3, 2025 |
| Oct 3, 2025 | SOpen-market sale Common Stock | -119,347 | $0.26 | $31k | 0 | Oct 3, 2025 |
Related signals
Other insiders at Carisma Therapeutics Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 20Weak | CARMsell Carisma Therapeutics Inc. | Michael Klichinsky Chief Scientific Officer | $14k 56,982 shares | -100% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.